Drugs / BCD 121
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03103451 | Nov 2016 → May 2017 | — | Biocad | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD 121 | “A Comparative Randomized Single-Blind Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Single Escalating Subcutaneous Doses of...” NCT03103451 ↗ |
| Action | Inhibit | “Simultaneous blockade of IL-17 and TNFa” NCT03103451 ↗ |
| Modality | Monoclonal antibody | “novel humanized monoclonal bispecific antibody” NCT03103451 ↗ |
| Route | Subcutaneous | “single subcutaneous injection” NCT03103451 ↗ |